Genflow Biosciences plc (GENFF)

Market Cap	12.77M +36.9%
Revenue (ttm)	n/a
Net Income	-2.47M
EPS	-0.01
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	72,218
Open	0.0300
Previous Close	0.0300
Day's Range	0.0300 - 0.0300
52-Week Range	0.0100 - 0.0645
Beta	2.26
RSI	50.84
Earnings Date	May 6, 2026

About Genflow Biosciences

Genflow Biosciences plc, together with its subsidiaries, engages in the research and development of gene therapy targeting the upstream biology of aging in the United Kingdom and Belgium. The company operates as a pre-clinical biotechnology company that focuses on developing biological interventions aimed at tackling the effects of aging, slowing, and halting the aging process, as well as reducing the incidence of age-related diseases. Its lead drug candidate is GF-1002, a suspension of an adeno-associated viral vector-based gene therapy for in...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2020
• Employees: 5
• Stock Exchange: OTCMKTS
• Ticker Symbol: GENFF

Financial Performance

Financial numbers in GBP